Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer

被引：168

作者：

Arrington, Amanda K. ^{[1
]}

Heinrich, Eileen L. ^{[1
]}

Lee, Wendy ^{[1
]}

Duldulao, Marjun ^{[1
]}

Patel, Supriya ^{[2
]}

Sanchez, Julian ^{[1
]}

Garcia-Aguilar, Julio ^{[3
]}

Kim, Joseph ^{[1
]}

机构：

[1] City Hope Natl Med Ctr, Ctr Comprehens Canc, Div Surg Oncol, Duarte, CA 91010 USA

[2] Univ So Calif, Dept Surg, Los Angeles, CA 90001 USA

[3] Mem Sloan Kettering Canc Ctr, Div Colorectal Surg, New York, NY 11597 USA

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2012年 / 13卷 / 10期

关键词：

KRAS; colorectal cancer; colon cancer; EGFR; Let7; ras; oncogenes; GROWTH-FACTOR RECEPTOR; KIRSTEN RAS MUTATIONS; HUMAN COLON-CANCER; GENETIC ALTERATIONS; 1ST-LINE TREATMENT; RECTAL-CANCER; KI-RAS; POINT MUTATIONS; HUMAN-LUNG; CETUXIMAB;

D O I：

10.3390/ijms131012153

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

The RAS gene family is among the most studied and best characterized of the known cancer-related genes. Of the three human ras isoforms, KRAS is the most frequently altered gene, with mutations occurring in 17%-25% of all cancers. In particular, approximately 30%-40% of colon cancers harbor a KRAS mutation. KRAS mutations in colon cancers have been associated with poorer survival and increased tumor aggressiveness. Additionally, KRAS mutations in colorectal cancer lead to resistance to select treatment strategies. In this review we examine the history of KRAS, its prognostic value in patients with colorectal cancer, and evidence supporting its predictive value in determining appropriate therapies for patients with colorectal cancer.

引用

页码：12153 / 12168

页数：16

共 85 条

[1]

Role of anti-oncomirs miR-143 and-145 in human colorectal tumors [J].

Akao, Y. ;

Nakagawa, Y. ;

Hirata, I. ;

Iio, A. ;

Itoh, T. ;

Kojima, K. ;

Nakashima, R. ;

Kitade, Y. ;

Naoe, T. .

CANCER GENE THERAPY, 2010, 17 (06) :398-408

[2]

let-7 microRNA functions as a potential growth suppressor in human colon cancer cells [J].

Akao, Yukihiro ;

Nakagawa, Yoshihito ;

Naoe, Tomoki .

BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2006, 29 (05) :903-906

[3]

MOST HUMAN CARCINOMAS OF THE EXOCRINE PANCREAS CONTAIN MUTANT C-K-RAS GENES [J].

ALMOGUERA, C ;

SHIBATA, D ;

FORRESTER, K ;

MARTIN, J ;

ARNHEIM, N ;

PERUCHO, M .

CELL, 1988, 53 (04) :549-554

[4]

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[5]

microRNAs: Tiny regulators with great potential [J].

Ambros, V .

CELL, 2001, 107 (07) :823-826

[6]

The functions of animal microRNAs [J].

Ambros, V .

NATURE, 2004, 431 (7006) :350-355

[7]

Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].

Andreyev, HJN ;

Norman, AR ;

Cunningham, D ;

Oates, J ;

Dix, BR ;

Iacopetta, BJ ;

Young, J ;

Walsh, T ;

Ward, R ;

Hawkins, N ;

Beranek, M ;

Jandik, P ;

Benamouzig, R ;

Jullian, E ;

Laurent-Puig, P ;

Olschwang, S ;

Muller, O ;

Hoffmann, I ;

Rabes, HM ;

Zietz, C ;

Troungos, C ;

Valavanis, C ;

Yuen, ST ;

Ho, JWC ;

Croke, CT ;

O'Donoghue, DP ;

Giaretti, W ;

Rapallo, A ;

Russo, A ;

Bazan, V ;

Tanaka, M ;

Omura, K ;

Azuma, T ;

Ohkusa, T ;

Fujimori, T ;

Ono, Y ;

Pauly, M ;

Faber, C ;

Glaesener, R ;

de Goeij, AFPM ;

Arends, JW ;

Andersen, SN ;

Lövig, T ;

Breivik, J ;

Gaudernack, G ;

Clausen, OPF ;

De Angelis, P ;

Meling, GI ;

Rognum, TO ;

Smith, R .

BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696

[8]

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study [J].

Andreyev, HJN ;

Norman, AR ;

Cunningham, D ;

Oates, JR ;

Clarke, PA .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) :675-684

[9]

Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]

[10]

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website [J].

Bamford, S ;

Dawson, E ;

Forbes, S ;

Clements, J ;

Pettett, R ;

Dogan, A ;

Flanagan, A ;

Teague, J ;

Futreal, PA ;

Stratton, MR ;

Wooster, R .

BRITISH JOURNAL OF CANCER, 2004, 91 (02) :355-358

← 1 2 3 4 5 6 7 8 9 →